Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 11Phase 1/2 4Phase NA 2Phase EARLY_PHASE1 2Phase 3 2

Status

Recruiting 10Completed 6Unknown 4Terminated 4Active not recruiting 4Withdrawn 2Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 122Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 86Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 42Myelodysplastic Syndromes 41Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Carcinoma, Hepatocellular 33Triple Negative Breast Neoplasms 32Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

sotrastaurin 1entrectinib 1binimetinib 1RNA, Messenger 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Uveal Melanoma × Clear all
NCT04589832 2023-11-22

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Hoosier Cancer Research Network

Phase 1/2 Terminated
6 enrolled 9 charts
Dermatologic

Uveal Melanoma

NCT02743611 2023-10-05

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Bellicum Pharmaceuticals

Phase 1/2 Terminated
4 enrolled 9 charts
DermatologicMyeloidOther hematologic neoplasm

Uveal Melanoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01801358 2020-09-16

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Array BioPharma

Phase 1/2 Terminated
38 enrolled 31 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00929019 2018-12-07

Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Radboud University Medical Center

Phase 1/2 Terminated
23 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡